2 Information about lenalidomide

Marketing authorisation indication

2.1 Lenalidomide (Revlimid, Celgene) is indicated for 'the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics. This technology appraisal guidance makes recommendations outside of the marketing authorisation for lenalidomide. The dosage schedule recommended by NICE is 10 mg per day on days 1 to 21 of a 28‑day cycle.


2.3 The list price for lenalidomide is £3,780 per pack of 21 capsules, each containing 10 mg of the active ingredient (excluding VAT; BNF online, November 2020). The company has a commercial arrangement. This makes lenalidomide available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)